Scientists from the Terasaki Institute for Biomedical Innovation have developed a nanoengineered bioink with improved bonding and cross-linking capabilities for 3D bioprinting of tumor models.
Beam shares promising first clinical data on gene editing treatment for a lung and liver disease
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
March 11, 2025